Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza virus vaccine 2009-2010 formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Participants aged 18 to 59 years at enrollment. |
| Group 2 | EXPERIMENTAL | Participants aged 60 years or older at enrollment. |
| Name | Type | Description |
|---|---|---|
| Influenza virus vaccine 2009-2010 formulation | BIOLOGICAL | 0.1 mL, Intradermal |
Inclusion Criteria: * Aged 18 to 59 years (i.e., to the day before the 60th birthday) or 60 years or older (from the day of the 60th birthday) on the day of inclusion * Provision of a signed informed consent * Able to attend all scheduled visits and comply with all trial procedures * For a woman of...
Influenza virus vaccine 2009-2010 formulation is used for the prevention of influenza. It is a seasonal influenza vaccine developed for the 2009-2010 Northern Hemisphere season. The vaccine is administered via the intradermal route and is intended for use in adults aged 18 years and older.
Influenza virus vaccine 2009-2010 formulation is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is responsible for the research, development, and manufacturing of this seasonal influenza vaccine.
Influenza virus vaccine 2009-2010 formulation is in Phase 2 clinical development. It is an investigational vaccine and has not been approved for commercial use. The Phase 2 trial has been completed, and the vaccine is no longer in active clinical testing.
Influenza virus vaccine 2009-2010 formulation has been studied in one clinical trial, identified as NCT00945438. This Phase 2 study, titled 'Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)', was conducted in France and enrolled 131 participants. The trial has been completed.
Influenza virus vaccine 2009-2010 formulation is not FDA approved. It is an investigational vaccine that has completed a Phase 2 clinical trial. The vaccine is still in clinical development and has not received regulatory approval for marketing in the United States or elsewhere.